Evaluation of the Inhibitory Effects of Bavachinin and Bavachin on Human Monoamine Oxidases A and B
Monoamine oxidase B inhibitors (MAO-BIs) are used in the early management of Parkinson’s disease (PD). Long-term suspected side effects of MAO-B classical inhibitors established the need for safer alternative therapeutic agents. In our study, the flavanone bavachinin (BNN) and its analog bavachin (BVN) found in the seeds ofPsoralea corylifoliaL. ethanolic extract (PCSEE) were investigated for theirhumanMAO-A and MAO-B (hMAO-A andhMAO-B) inhibition. Both PCSEE and BNN effectively reducedhMAO-B activity more thanhMAO-A while BVN had activating effects. BNN showed selectivehMAO-B inhibition (IC50 ~ 8.82 μM) more thanhMAO-A (IC502009;~ 189.28 μM). BNN in the crude extract was determined by HPLC, also validated by TLC showing a yield of 0.21% PCSEE dry weight. BNN competitively inhibitedhMAO-A andhMAO-B, with a lowerhMAO-BKithanhMAO-AKiby 10.33-fold, and reducedhMAO-BKm/Vmaxefficiency ratio to be comparable to the standard selegiline. Molecular docking examination of BNN and BVN predicted an indirect role of BNN C7-methoxy group for its higher affinity, selectivity, and reversibility as an MAO-BI. These findings suggest that BNN, which is known to be a potent PPAR-γagonist, is a selective and competitivehMAO-B inhibitor and could be used in the management of PD.